Ganciclovir prophylaxis shows no respiratory support-free day, mortality benefit in sepsis

Key takeaways:

Studied adults had sepsis-associated respiratory failure and were cytomegalovirus seropositive.

Those receiving ganciclovir had a similar mean number of respiratory support-free days to those receiving placebo.

SAN FRANCISCO — Receiving ganciclovir prophylaxis did not have a benefit on respiratory support-free days vs. placebo in adults with sepsis-associated respiratory failure and cytomegalovirus-seropositivity, according to phase 3 trial data.

This trial, which also showed a higher proportion of death among those receiving ganciclovir, was presented at the American Thoracic Society International Conference.

Data were derived from Stapleton R. Ganciclovir to prevent reactivation of cytomegalovirus in patients with sepsis-associated acute respiratory failure: A phase 3